NASDAQ
16.90USD
+0.16 (+0.96%)
We have scored 8 news catalysts on Aurinia Pharmaceuticals Inc. (AUPH) over the past 12 months. The biggest single-day move next to one of them came Jun 7, 2026, when AUPH closed −3.2%: “Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million”. Coverage across the window leans positive (average ticker sentiment +0.40). Most of the impact sits in price momentum and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.2B
P/E
—
EPS
—
Beta
1.41
52W range
11.48-19.25
Day range
16.63–17.01
Open
16.73
Prev close
16.74
Volume
783.1K
Avg volume
1.2M
Dividend
0.00
IPO
2014-09-03
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Aurinia Pharmaceuticals Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for AUPH: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
